Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.

Key Figures

ASX announcement date: April 21, 2026

1 metrics

ASX announcement date April 21, 2026 Date of “Telix Notice of AGM, Proxy Form and Online Guide” filing in Melbourne

Key Terms

Form 6-K, foreign private issuer, Australian Securities Exchange

3 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Australian Securities Exchange financial

"filed an announcement with the Australian Securities Exchange titled “Telix Notice of AGM, Proxy Form and Online Guide”"

Australian Securities Exchange is Australia’s main marketplace where stocks, bonds, ETFs and other tradable financial instruments are bought and sold. Think of it as a large, regulated marketplace that shows current prices, matches buyers and sellers, and enforces rules to keep trading fair and orderly—information and liquidity from the exchange directly affect how easy it is to trade an investment and how its market price is determined.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On April 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix Notice of AGM, Proxy Form and Online Guide,” a copy of which is attached to this Form 6-K as Exhibit 99.1.

99.1 ASX Announcement – April 21, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: April 21, 2026	By:	/s/ Christian Krautkramer
		Name: Christian Krautkramer
		Title: Group General Counsel

FAQ

What does Telix Pharmaceuticals (TLX) report in this Form 6-K?

Telix Pharmaceuticals reports that it has filed an announcement with the Australian Securities Exchange titled “Telix Notice of AGM, Proxy Form and Online Guide.” This announcement is attached as Exhibit 99.1, making the shareholder meeting materials available to U.S. investors through the Form 6-K.

What is contained in Exhibit 99.1 to Telix Pharmaceuticals’ Form 6-K?

Exhibit 99.1 contains the Telix announcement lodged with the Australian Securities Exchange titled “Telix Notice of AGM, Proxy Form and Online Guide.” This exhibit provides details and materials relating to Telix’s AGM, proxy form, and an online guide for shareholders referenced in the title.

When did Telix Pharmaceuticals file the AGM-related announcement?

Telix Pharmaceuticals filed the announcement titled “Telix Notice of AGM, Proxy Form and Online Guide” on April 21, 2026 in Melbourne, Australia. The same date appears on the Form 6-K, which furnishes this Australian Securities Exchange announcement to U.S. markets as an exhibit.

Who signed the Telix Pharmaceuticals Form 6-K related to the AGM notice?

The Form 6-K was signed on behalf of Telix Pharmaceuticals Limited by Christian Krautkramer, who is identified as the Group General Counsel. His electronic signature “/s/ Christian Krautkramer” appears in the signature block alongside the company name and date.

Why is Telix Pharmaceuticals classified as a foreign private issuer in this filing?

Telix Pharmaceuticals is described as a foreign private issuer because it files reports on Form 6-K and indicates it files annual reports under Form 20-F. This status reflects that the company is organized outside the United States and follows foreign issuer reporting standards.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 2.9 KB